This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update

Table 38: Product Profile - Tabalumab 76

Table 39: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 77

Table 40: Tabalumab SWOT Analysis, 2012 78

Table 41: Product Profile - Fostamatinib 79

Table 42: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three 80

Table 43: Fostamatinib SWOT Analysis, 2012 82

Table 44: Product Profile - RAVAX 83

Table 45: RAVAX SWOT Analysis, 2012 86

Table 46: Product Profile - Secukinumab 87

Table 47: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 88

Table 48: Secukinumab SWOT Analysis, 2012 90

Table 49: Product Profile - Masitinib 91

Table 50: ACR Responses for Masitinib in the ITT Population (12 Weeks) 92

Table 51: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 93

Table 52: Masitinib SWOT Analysis, 2012 95

Table 53: Product Profile - Baricitinib 96

Table 54: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12 97

Table 55: Safety of 4 and 8mg Baricitinib at Week 12 98

Table 56: Laboratory Values of 4 and 8mg Baricitinib at Week 12 98

Table 57: Baricitinib SWOT Analysis, 2012 99

Table 58: Product Profile - Sarilumab 100

Table 59: MOBILITY Study Results for Sarilumab at Week 12 101

Table 60: Sarilumab SWOT Analysis, 2012 102

Table 61: Product Profile - Sirukumab 103

Table 62: Sirukumab SWOT Analysis, 2012 105

Table 63: Sales Forecasts ($m) for Rheumatoid Arthritis in the United Kingdom 107

Table 64: Key Events Impacting Sales for Rheumatoid Arthritis in the United Kingdom, 2012 109

Table 65: Rheumatoid Arthritis Market - Drivers and Barriers in the United Kingdom, 2012 109

Table 66: Key Launch Dates 124

Table 67: Key Patent Expiries 124

Table 68: Physicians Surveyed, By Country 132

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,888.86 -87.45 -0.49%
S&P 500 2,077.15 -9.09 -0.44%
NASDAQ 4,925.04 -22.4010 -0.45%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs